Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of GWP42003 + GWP42004 for antipsychotic-associated weight gain and dyslipidemia
2011-000180-28Phase 2Terminated
- Sponsor
- GW Pharmaceuticals
- Start
- Apr 2011
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in N/A and dyslipidemia comparing GWP42003 + GWP42004 with Placebo (2 arms). Primary endpoint: Change in body weight from baseline. Started Apr 2011; status: terminated.
02
Drugs
cannabidioltetrahydrocannabivarin
03
Conditions
N/Adyslipidemia
Beyond the preview
Go deeper on 2011-000180-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000180-28.